ArticleCancer biology & medicine2016
Genetic and molecular changes in ovarian cancer.
Article in Cancer biology & medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.Lancet (London, England) · 2022Trial
- Subtype Characterization of Ovarian Cancer Cell Lines Using Machine Learning and Network Analysis: A Pilot Study.Cancers · 2025Article
- Review
- Causal role of ischemic heart disease in ovarian cancer subtypes.Discover oncology · 2025Article
- Silencing of Epidermal Growth Factor-like Domain 8 Promotes Proliferation and Cancer Aggressiveness in Human Ovarian Cancer Cells by Activating ERK/MAPK Signaling Cascades.International journal of molecular sciences · 2024Article
- Pathogenesis of Endometriosis and Endometriosis-Associated Cancers.International journal of molecular sciences · 2024Review
- Review
- A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.Cureus · 2024Review
- Advanced stage, high-grade primary tumor ovarian cancer: a multi-omics dissection and biomarker prediction process.Scientific reports · 2023Article
- Spectrum of Ovarian Incidentalomas: Diagnosis and Management.The British journal of radiology · 2023Review
- DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.Cancers · 2023Review
- Metastasis of ovarian cancer to nasal skin and skin on the trunk: a rare case report.Frontiers in oncology · 2023Article
- Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer.Pharmaceutical research · 2023Review
- 2bRAD-M reveals the difference in microbial distribution between cancerous and benign ovarian tissues.Frontiers in microbiology · 2023Article
- Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.Frontiers in immunology · 2023Article
- Germline pathogenic variants associated with ovarian cancer: A historical overview.Gynecologic oncology reports · 2022Review
- The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.International journal of molecular sciences · 2022Review
- MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.Gynecologic oncology reports · 2022Article
- Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.Oncotarget · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer represents the most lethal gynecological malignancy in the developed world, and can be divided into five main histological subtypes: high grade serous, endometrioid, clear cell, mucinous and low grade serous. These subtypes represent distinct disease entities, both clinically and at the molecular level. Molecular analysis has revealed significant genetic heterogeneity in ovarian cancer, particularly within the high grade serous subtype. As such, this subtype has been the focus of much research effort to date, revealing molecular subgroups at both the genomic and transcriptomic level that have clinical implications. However, stratification of ovarian cancer patients based on the underlying biology of their disease remains in its infancy. Here, we summarize the molecular changes that characterize the five main ovarian cancer subtypes, highlight potential opportunities for targeted therapeutic intervention and outline priorities for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.